Table II.
Genotype frequencies of the MDM2 309T>G polymorphism among controls and cases and their association with lung cancer risk.
| Adjusted OR (95% CI)a | |||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| Variable | No. | T/T (%) | T/G (%) | G/G (%) | T/T vs. G/G | T/T vs. T/G+G/G | T/T+T/G vs. G/G |
| Control | 700 | 152 (21.7) | 335 (47.9) | 213 (30.4) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) |
| Case | 762 | 153 (20.1) | 379 (49.7) | 230 (30.2) | 1.18 (0.76–1.80) | 1.25 (0.87–1.81) | 0.98 (0.71–1.37) |
| Femaleb | 290 | 53 (18.3) | 143 (49.3) | 94 (32.4) | 1.31 (0.91–1.87) | 1.51 (0.83–2.75) | 1.34 (0.76–2.34) |
| Maleb | 472 | 100 (21.2) | 236 (50.0) | 136 (28.8) | 0.94 (0.55–1.60) | 1.13 (0.72–1.79) | 0.83 (0.55–1.24) |
| AD | 487 | 101 (20.7) | 233 (47.8) | 153 (31.4) | 1.05 (0.84–1.31) | 1.14 (0.77–1.67) | 1.02 (0.72–1.44) |
| SQ | 182 | 35 (19.2) | 98 (53.8) | 49 (26.9) | 1.06 (0.77–1.46) | 1.42 (0.80–2.49) | 0.87 (0.52–1.43) |
| EGFR-WT-AD | 207 | 41 (19.8) | 102 (49.3) | 64 (30.9) | 1.09 (0.83–1.42) | 1.28 (0.80–2.05) | 1.01 (0.67–1.52) |
| EGFR-Mt-AD | 175 | 39 (22.3) | 78 (44.6) | 58 (33.1) | 1.00 (0.75–1.35) | 0.97 (0.58–1.61) | 1.04 (0.66–1.64) |
| Never-smoker | 251 | 43 (17.1) | 129 (51.4) | 79 (31.5) | 1.07 (0.75–1.55) | 1.46 (0.78–2.73) | 0.89 (0.52–1.54) |
| Light smoker | 258 | 49 (19.0) | 127 (49.2) | 82 (31.8) | 1.09 (0.85–1.41) | 1.30 (0.83–2.03) | 1.00 (0.68–1.49) |
| Heavy smoker | 246 | 57 (23.2) | 120 (48.8) | 69 (28.0) | 1.00 (0.71–1.41) | 1.07 (0.60–1.92) | 0.95 (0.55–1.64) |
a
Adjusted for gender, age and smoking status.
b
Adjusted for age and smoking status.
MDM2, murine double minute 2; OR, odds ratio; CI, confidence interval; AD, adenocarcinoma; SQ, squamous cell carcinoma; EGFR, epidermal growth factor receptor; WT, wild-type; Mt; mutant.